Piper Jaffray Cuts Price Target on Merck (MRK) Ahead of Lilly's SGLT2 Inhibitor Presentation
Tweet Send to a Friend
Piper Jaffray maintained a Neutral rating on Merck (NYSE: MRK), and cut the price target to $60.00 (from $62.00), ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
